PITTSBURGH--(BUSINESS WIRE)--Lipella Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on improving cancer survivorship, today announced it has begun recruiting patients in the ...

Please provide your email address to receive an email when new articles are posted on . BK virus-specific cytotoxic T lymphocytes from healthy donors appeared safe and effective for patients with BK ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug ...

(RTTNews) - Biotechnology company Lipella Pharmaceuticals Inc. (LIPO) announced top line results for its recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug ...

BK virus-associated hemorrhagic cystitis (BKV-HC) is a common complication of allogenic hematopoietic stem cell transplantation (AHSCT), particularly in recipients of alternative donor transplants, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio The FDA granted orphan drug designation ...

I encountered my most memorable patient while working as a urology nurse practitioner at a large urban hospital. The patient was 70 years old, alert and oriented and lived in a nursing home. He had a ...

Posoleucel is being investigated for the treatment and prevention of serious diseases caused by 6 viral pathogens. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ...

A therapy derived from the eggs of parasitic worms helps to protect against one of chemotherapy's debilitating side effects by significantly downregulating major proinflammatory pathways and reducing ...

Matinas Biopharma Holdings, Inc. (AMEX:MTNB) shares are trading higher on Wednesday after the company announced complete clinical resolution of a patient's recurrent hemorrhagic cystitis following ...

On the basis of these findings, we encourage a clinical trial of risperidone in late-onset post-transplant HC, particularly in non-responders to intravesical sodium hyaluronate. Given the high ...